Trial Profile
A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary)
- Indications Congenital ichthyosiform erythroderma
- Focus Adverse reactions; Proof of concept
- Sponsors Patagonia Pharmaceuticals
- 15 Feb 2024 According to Timber Pharmaceuticals media release, Timber Pharmaceuticals has changed its name to Trex Wind-down
- 07 Mar 2022 Results published in the Journal of the American Academy of Dermatology
- 01 Oct 2021 According to a Timber Pharmaceuticals media release, results from this trial will be presented at the European Academy of Dermatology and Venereology's (EADV) 30th anniversary congress, 2021.